Durvalumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Durvalumab
- Durvalumab: An Anti-PD-L1 Checkpoint Inhibitor — Predicted New Indication: Prostatic Urethra Urothelial Carcinoma
Durvalumab: An Anti-PD-L1 Checkpoint Inhibitor — Predicted New Indication: Prostatic Urethra Urothelial Carcinoma
One-Sentence Summary
Durvalumab is an anti-PD-L1 monoclonal antibody (immune checkpoint inhibitor); this evidence pack does not document its original approved indication or detailed mechanism of action data, and the drug is currently not marketed in Finland. The TxGNN model's top-ranked prediction is Prostatic Urethra Urothelial Carcinoma (score 99.98%), but this specific prediction is currently supported by no clinical trials and no literature — it is a model-only hypothesis. Note: among the 10 candidates in this pack, two other urothelial/gynecologic-carcinoma indications (ranks 3 and 6) do have supporting trial and/or literature evidence — see the Conclusion for details.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (original_indications empty; Finland has 0 licenses on file) |
| Predicted New Indication | Prostatic Urethra Urothelial Carcinoma |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only, no trials or literature) |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for durvalumab in this evidence pack (flagged as a High-severity data gap). Based on information present in the supporting rationale fields, durvalumab is an anti-PD-L1 monoclonal antibody that works by blocking the PD-1/PD-L1 checkpoint pathway, restoring T-cell mediated anti-tumor immune activity — a mechanism already established as a therapeutic strategy across several urothelial and immunogenic tumor types represented elsewhere in this same prediction set.
Prostatic urethra urothelial carcinoma shares tissue origin with bladder and renal pelvis urothelial carcinoma — both part of the broader urothelial carcinoma family. The rationale for this specific prediction is a mechanistic extrapolation: because PD-L1 checkpoint blockade has known biological relevance in urothelial carcinoma generally, the model infers the same may hold for the prostatic urethra subtype.
However, this extrapolation is not yet backed by any disease-specific trial or publication — no clinicaltrials.gov, ICTRP, or PubMed record was found for durvalumab in prostatic urethra urothelial carcinoma specifically (query log IDs 5–7, all zero results). The mechanistic plausibility is inherited from the urothelial-carcinoma class as a whole rather than from direct evidence in this exact histologic subtype.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Durvalumab currently has no marketing authorization on file in Finland (market_status: 未上市, total_licenses: 0). No product/dosage-form information is available.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (anti-PD-L1 immune checkpoint inhibitor) — not a conventional cytotoxic chemotherapy agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (prostatic urethra urothelial carcinoma) has evidence level L5 — a TxGNN model score with zero corroborating clinical trials or literature. In addition, package insert warnings/contraindications for durvalumab are flagged as a Blocking data gap (DG001), which by itself prevents this candidate from entering the S1 safety pre-assessment stage regardless of efficacy evidence.
To proceed, the following is needed:
- TFDA/Fimea package insert (warnings, contraindications) to clear the Blocking data gap (DG001) and enable S1 safety pre-assessment
- Confirmed mechanism of action and original approved indication documentation (DG002)
- Disease-specific preclinical or early clinical data for prostatic urethra urothelial carcinoma, since current support is mechanistic extrapolation only
Note for prioritization: two other candidates in this same prediction set have materially stronger evidence and may warrant separate evaluation ahead of this one:
- Infiltrating bladder urothelial carcinoma, sarcomatoid variant (rank 3, L3, decision stage S1) — a Phase 2 trial (NCT03912818, terminated, n=7) graded "A" for disease-specificity, plus a supporting Phase 1 trial (NCT02812420).
- Endocervical carcinoma (rank 6, L2, decision stage S2) — two trials (NCT04065269 Phase 2 ongoing n=174; NCT03452332 Phase 1 completed n=20) and one supporting review (PMID 37467967).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.